A Phase 1 interventional study of olaparib in Cancer and Advanced Solid Malignancies, sponsored by AstraZeneca. Completed at 3 sites in Japan. Open to participants aged 20 Years to 130 Years. Per ClinicalTrials.gov, last updated 2018-01-16.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study will be to investigate the safety and tolerability of olaparib tablet when given orally to Japanese patients with advanced solid malignancies. In addition, the pharmacokinetic profile, MTD (if possible) and efficacy of olaparib will be investigated.
MTD - maximum tolerated dose
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 23 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
olaparib tablet
Drug: olaparib
tablet oral
Number of Participants With Adverse Events
An adverse event is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. This was recorded if it happend from the start dose to 30 days after the last of study drug.
Time frame: From the start dose to 30 days after the last dose of study drug
Number of Participants With Dose Limiting Toxicities
Dose Limiting Toxicities were defined as study specific events that is determined to be possibly or probably related to olaparib (as determined by the investigator) and occurring during the first cycle of treatment (28 days after the first dose), irrespective of whether the toxicity resolved.
Time frame: From the start dose to 28 days after the first dose of study drug
Cmax Following Single Dosing
Time frame: Day 1: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours at post-dose
Cmax Following Multiple Dosing
Time frame: Day 15: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours at post-dose
Tmax Following Single Dosing
Time frame: Day 1: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours at post-dose
Tmax Following Multiple Dosing
Time frame: Day 15: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours at post-dose
AUC Following Single Dosing
Time frame: Day 1: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours at post-dose
AUC at Steady State Following Multiple Dosing
Time frame: Day 15: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours at post-dose
First patient enrolled on 25 March 2013. Last patient enrolled on 31 October 2013. Data cut off on 31 July 2014.
| Milestone | 200 mg Bid, Dose Escalation Part | 300 mg Bid, Dose Escalation Part | 300 mg Bid, Expansion Part |
|---|---|---|---|
| Started | 4 | 7 | 12 |
| Completed | 1 | 0 | 1 |
| Not completed | 3 | 7 | 11 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Withdrew: Adverse event | 1 | 1 | 0 |
| Withdrew: Lack of efficacy | 2 | 6 | 9 |
| Withdrew: Death | 0 | 0 | 1 |
An adverse event is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. This was recorded if it happend from the start dose to 30 days after the last of study drug.
| Participants | 200 mg Bid, Dose Escalation Part | 300 mg Bid, Dose Escalation Part | 300 mg Bid, Expansion Part |
|---|---|---|---|
| At least 1 Adverse Events (AE) | 4 | 7 | 10 |
| At least 1 AE of CTCAE Grade 3 or higher | 1 | 3 | 1 |
| At least 1 Serious Adverse Events (SAE) | 1 | 0 | 0 |
Dose Limiting Toxicities were defined as study specific events that is determined to be possibly or probably related to olaparib (as determined by the investigator) and occurring during the first cycle of treatment (28 days after the first dose), irrespective of whether the toxicity resolved.
| Participants | 200 mg Bid, Dose Escalation Part | 300 mg Bid, Dose Escalation Part |
|---|---|---|
| Number of Participants With Dose Limiting Toxicities | 0 | 0 |
| μg/mL | 200 mg Bid, Dose Escalation Part | 300 mg Bid, Dose Escalation Part |
|---|---|---|
| Cmax Following Single Dosing | 6.697 ± 95.69 | 7.743 ± 34.76 |
| μg/mL | 200 mg Bid, Dose Escalation Part | 300 mg Bid, Dose Escalation Part |
|---|---|---|
| Cmax Following Multiple Dosing | 7.668 ± 46.93 | 8.434 ± 35.05 |
| hour | 200 mg Bid, Dose Escalation Part | 300 mg Bid, Dose Escalation Part |
|---|---|---|
| Tmax Following Single Dosing | 2.00 ± 95.69 | 1.98 ± 34.76 |
| hour | 200 mg Bid, Dose Escalation Part | 300 mg Bid, Dose Escalation Part |
|---|---|---|
| Tmax Following Multiple Dosing | 1.50 ± 46.93 | 3.00 ± 35.05 |
| μg*h/mL | 200 mg Bid, Dose Escalation Part | 300 mg Bid, Dose Escalation Part |
|---|---|---|
| AUC Following Single Dosing | 61.97 ± 473.4 | 46.21 ± 64.64 |
| μg*h/mL | 200 mg Bid, Dose Escalation Part | 300 mg Bid, Dose Escalation Part |
|---|---|---|
| AUC at Steady State Following Multiple Dosing | 36.50 ± 71.94 | 52.34 ± 68.17 |
Collected over Through treatment and 30-day follow-up period, an average of about 4 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 200 mg Bid, Dose Escalation Part | — | 1/4 (25%) | 4/4 (100%) |
| 300 mg Bid, Dose Escalation Part | — | 0/7 (0%) | 7/7 (100%) |
| 300 mg Bid, Expansion Part | — | 0/12 (0%) | 10/12 (83.3%) |
| Event | 200 mg Bid, Dose Escalation Part | 300 mg Bid, Dose Escalation Part | 300 mg Bid, Expansion Part |
|---|---|---|---|
| IleusGastrointestinal disorders | 1/4 | 0/7 | 0/12 |
| Event | 200 mg Bid, Dose Escalation Part | 300 mg Bid, Dose Escalation Part | 300 mg Bid, Expansion Part |
|---|---|---|---|
| NauseaGastrointestinal disorders | 1/4 | 6/7 | 3/12 |
| AnaemiaBlood and lymphatic system disorders | 0/4 | 4/7 | 2/12 |
| Decreased appetiteMetabolism and nutrition disorders | 0/4 | 4/7 | 3/12 |
| White blood cell count decreasedInvestigations | 0/4 | 3/7 | 2/12 |
| ConstipationGastrointestinal disorders | 0/4 | 2/7 | 4/12 |
| DiarrhoeaGastrointestinal disorders | 0/4 | 2/7 | 2/12 |
| DyspepsiaGastrointestinal disorders | 0/4 | 2/7 | 1/12 |
| ProteinuriaRenal and urinary disorders | 0/4 | 2/7 | 0/12 |
| MalaiseGeneral disorders | 0/4 | 2/7 | 2/12 |
| Neutrophil count decreasedInvestigations | 0/4 | 2/7 | 2/12 |
| Age, Continuous(Years) | 200 mg Bid, Dose Escalation Part | 300 mg Bid, Dose Escalation Part | 300 mg Bid, Expansion Part | Total |
|---|---|---|---|---|
| Mean | 42.0 ± 8.68 | 55.4 ± 8.98 | 57.3 ± 12.43 | 54.1 ± 11.94 |
| Sex: Female, Male(Participants) | 200 mg Bid, Dose Escalation Part | 300 mg Bid, Dose Escalation Part | 300 mg Bid, Expansion Part | Total |
|---|---|---|---|---|
| Sex — Female | 4 | 4 | 7 | 15 |
| Sex — Male | 0 | 3 | 5 | 8 |
| Primary tumour location(Participants) | 200 mg Bid, Dose Escalation Part | 300 mg Bid, Dose Escalation Part | 300 mg Bid, Expansion Part | Total |
|---|---|---|---|---|
| Breast | 1 | 1 | 3 | 5 |
| Colorectal | 0 | 0 | 1 | 1 |
| Lung | 0 | 1 | 2 | 3 |
| Peritoneum | 0 | 0 | 1 | 1 |
| Pancreas | 0 | 1 | 0 | 1 |
| Ovary | 0 | 2 | 2 | 4 |
| Uterus | 1 | 1 | 0 | 2 |
| Cervix | 2 | 0 | 0 | 2 |
| Colon | 0 | 0 | 1 | 1 |
| Gastric Antrum | 0 | 0 | 1 | 1 |
| Other | 0 | 1 | 1 | 2 |
Ran from Mar 2013 to primary completion in Aug 2016, 41 months.
Results were first posted in Dec 2017, 1 year 3 months after primary completion.
Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 41 months is close to that.
Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olaparib